title: NADPH-cytochrome P-450 reductase is involved in flunitrazepam reductive metabolism in Hep G2 and Hep 3B cells.
abstract: Flunitrazepam (FNTZ), like other benzodiazepines, has a high affinity for the benzodiazepine receptor within the gama-aminobutyric acid (GABA) complex. These affinities correlate with the pharmacological and therapeutic potencies of the drug. FNTZ is a drug commonly abused by young adults. In humans, FNTZ is oxidized to the major metabolites N-demethylflunitrazepam (DM FNTZ) and 3-hydroxyflunitrazepam (3-OH FNTZ) and reduced to 7-aminoflunitrazepam (7A FNTZ). Human CYP2C19 and CYP3A4 are the principal P-450 cytochromes involved in DM FNTZ and 3-OH FNTZ formation. However, it is not clear which enzyme is responsible for the reduction of FNTZ to 7-aminoflunitrazepam (7A FNTZ). In this study, the involvement of NADPH-cytochrome P-450 reductase in the conversion of FNTZ to 7A FNTZ was investigated in two human hepatoma cell lines, human lymphoblast microsomes specifically expressing human NADPH-cytochrome P-450 reductase and purified recombinant human HADPH-cytochrome P-450 reductase. Significantly more FNTZ was converted to 7A FNTZ in Hep G2 than in Hep 3B cells, and this difference was associated with the catalytic activity and protein levels of NADPH-cytochrome P-450 reductase in these cells. In Hep G2 cells, conversion of FNTZ to 7A FNTZ was effectively inhibited by alpha-lipoic acid, an NADPH-cytochrome P-450 reductase inhibitor. In addition, formation of 7A FNTZ by the microsomal fraction of Hep G2 cells was specifically inhibited by antibody against NADPH-cytochrome P-450 reductase. Under hypoxia (N2 85%; CO2 5%; H2 10%), human lymphoblast microsomes specifically expressing human NADPH-cytochrome P-450 reductase and purified recombinant human NADPH-P-450 reductase catabolized FNTZ to 7A FNTZ in a concentration-dependent manner. These results suggest that NADPH-cytochrome P-450 reductase is involved in the reductive metabolism of FNTZ to 7A FNTZ under hypoxic conditions.
authors.affiliation: Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan. fcpeng@ha.mc.ntu.edu.tw
authors.forename: Fu-Chuo
authors.initials: FC
authors.lastname: Peng
authors.forename: Hsin-Hui
authors.initials: HH
authors.lastname: Chaing
authors.forename: Sheng-Hui
authors.initials: SH
authors.lastname: Tang
authors.forename: Pei-Chun
authors.initials: PC
authors.lastname: Chen
authors.forename: Shao-Chun
authors.initials: SC
authors.lastname: Lu
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D004305:Dose-Response Relationship, Drug; D005445:Flunitrazepam / Q000378:metabolism*; D018757:GABA Modulators / Q000378:metabolism*; D006801:Humans; D008861:Microsomes; D009251:NADPH-Ferrihemoprotein Reductase / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D018757:GABA Modulators; D005445:Flunitrazepam; D009251:NADPH-Ferrihemoprotein Reductase